Comparison of Relative Survival and Cause-Specific Survival in Men With Prostate Cancer According to Age and Risk Category: A Nationwide, Population-Based Study

Andri Wilberg Orrason*, Hans Garmo, Johan Styrke, Paul W. Dickman, and Pär Stattin

* Correspondence to Andri Wilberg Orrason, Department of Surgical Sciences, Uppsala University Hospital, 751 85 Uppsala, Sweden (e-mail: andri.wilberg@surgsci.uu.se).

Initially submitted September 20, 2020; accepted for publication May 13, 2021.

Net survival, estimated in a relative survival (RS) or cause-specific survival (CSS) framework, is a key measure of the effectiveness of cancer management. We compared RS and CSS in men with prostate cancer (PCa) according to age and risk category, using Prostate Cancer data Base Sweden, including 168,793 men younger than age 90 years, diagnosed 1998–2016 with PCa. RS and CSS were compared according to age and risk category based on TNM (tumor, nodes, and metastases) stage, Gleason score, and prostate-specific antigen level. Each framework requires assumptions that are unlikely to be appropriate for PCa. Ten-year RS was substantially higher than CSS in men aged 80–89 with low-risk PCa: 125% (95% confidence interval: 113, 138) versus 85% (95% confidence interval: 82, 88). In contrast, RS and CSS were similar for men under age 70 and for all men with regional or distant metastases. Both RS and CSS produce biased estimates of net survival for men with low- and intermediate-risk PCa, in particular for men over 80. Due to biases, net survival is overestimated in analysis of RS but underestimated in analysis of CSS. These results highlight the importance of evaluating the underlying assumptions for each method, because the “true” net survival is expected to lie between the limits of RS and CSS.

cause-specific survival; net survival prostate cancer; prognosis; relative survival; survival

Prostate cancer (PCa) is a common cancer in high-resource countries. The incidence of PCa has risen during the last 2 decades, mostly due to an increased detection of low- and intermediate-risk disease due to testing of serum levels of prostate-specific antigen (PSA) and ensuing ultrasound guided biopsies of the prostate (1, 2). Concomitantly, there have been improvements in the workup and treatment of PCa, with large increases in the use of radical treatments, and in many countries, there has been a decline in PCa mortality (2–4).

In Sweden, the incidence of PCa, age-adjusted to the world population, increased over 1998–2017 from 74 to 94 per 100,000 men, and PCa mortality decreased from 22 to 14/100,000 (5). In men under age 80, the decrease in PCa mortality was around 50%, from 14 to 7 per 100,000, whereas in men age 80 or older, the mortality declined only 13%, from 868 to 755 per 100,000 (Figure 1).

Mortality is considered to be a robust measure of progress in cancer control because it is not substantially affected by overdiagnosis. However, the total change in PCa mortality has been quite modest, despite large efforts devoted to early detection and early treatment of PCa, due to the fact that a large proportion of men who die of PCa are over age 80, for whom PCa might be overreported as a cause of death (6, 7).

Mortality captures the combined effects of primary prevention (which affects incidence), secondary prevention, and treatment. It is also desirable to measure the effectiveness of cancer management (i.e., diagnosis and treatment) using a measure that is not affected by changes in incidence. Net survival is a measure of patient survival that is independent of changes in incidence and independent of background (noncancer) mortality. Net survival is interpreted as the probability of survival in the hypothetical situation in which death can occur only due the disease under study. It can be
estimated using 2 different frameworks; relative survival (RS), based on comparison with a disease-free background population, or cause-specific survival (CSS), based on classification of underlying cause of death.

In population-based studies of cancer survival, the relative survival framework is considered most suitable for estimating net survival (6, 8). RS requires the assumption that factors affecting survival, not captured by life tables (e.g., comorbidity and socioeconomic status), are similar in the study population and in the background population, whereas CSS requires correct classification of cause of death. However, in older men with PCa, these assumptions might not hold true due to incompatibility with respect to comorbidity in the general population and a higher risk of a misclassification of cause of death.

Multiple registry-based studies have compared these 2 measures of survival for men with PCa, and RS has consistently been higher than CSS (6, 7, 9–11). However, these studies did not include data on PCa risk category, and some of the studies used age groups with a cutoff of age 65 years, which is too low for meaningful analyses (9).

The aim of this study was to compare RS and CSS according to age and risk category in men with PCa in a large population-based cohort with comprehensive data on cancer characteristics, treatment, and cause of death. A unique feature of our study is that we have detailed data on comorbidity of both men with PCa and matched comparators, which can potentially be used to correct the well-known bias in RS.

METHODS

Registers

The National Prostate Cancer Register (NPCR) of Sweden holds information on 98% of all incident PCa cases since 1998, as compared with the Swedish Cancer Registry, to which reporting is mandated by law. NPCR contains detailed data on cancer characteristics, diagnostic workup, and primary treatment. Using the unique Swedish personal identity number, NPCR has been linked to a number of other nationwide health-care registers and demographic databases—including the Patient Registry, the Prescribed Drug Registry, the Cause of Death Registry, and the longitudinal integration database for health insurance and labor market studies—to construct the Prostate Cancer data Base Sweden (12). This research database also includes 5 matched comparators for each man with PCa. Comparators were randomly selected, using the Total Population Register maintained by Statistics Sweden, from all men in the population who were free of PCa at end of the year of diagnosis of the index case, resided in the same county as the case, and were born in the same year.

Study population

We used Prostate Cancer data Base Sweden, version 4.1, and categorized the study population by age and risk category at date of diagnosis. Age groups were defined, in years: <70, 70–79, and 80–89; men 90 years or older at diagnosis were excluded due to short life expectancy. Risk category was defined according to a modified National Comprehensive Cancer Network categorization: 1) low-risk: clinical (tumor, nodes, metastases) stage T1–T2, Gleason score 6, and PSA <10 ng/mL; 2) intermediate-risk: T1–T2 and Gleason score 7, or PSA 10–19.9 ng/mL; 3) high-risk or locally advanced: T3, Gleason score 8 or above, or PSA 20–49.9 ng/mL; 4) regional: T4, N1, or PSA 50–99.9 ng/mL; and 5) distant metastases: M1 or PSA ≥100 ng/mL.

Follow-up started at the date of diagnosis and ended at December 31, 2017, date of emigration, or date of death, whichever occurred first.
Statistical analysis

RS was estimated with the Ederer II method (13). Expected survival was calculated using survival probabilities from life tables generated from the Swedish population, matched by age and year of the study population (14). CSS was estimated with the Kaplan-Meier method (15). The so-called “complete” follow-up approach was applied in both methods as described by Brenner and Rachet (16). Estimates from both methods were plotted and stratified by age and risk category.

In order to maximize the comparability between the study population and the general population we repeated the RS analysis using PCA-free comparators in Prostate Cancer data Base Sweden instead of data from general life tables. Comparators were matched, by design, to the study population on age and calendar year at date of PCa diagnosis, as well as for factors not captured by general life tables (i.e., comorbidity, educational level, and marital/partnership status). Comorbidity at date of diagnosis was classified by use of the Charlson Comorbidity Index, which is a weighted sum of a number of International Classification of Diseases codes for discharge diagnoses excluding PCa in the Patient Registry (17). Comorbidity was classified into 4 levels: 0, 1, 2 or ≥3. In addition, a novel Drug Comorbidity Index was used that predicts an individual’s risk of death from any cause based on drug prescriptions the year prior to diagnosis (18). Matching of comparators was performed using cases diagnosed during 2007–2016. (The Drug Comorbidity Index was available from July 2005 when the Prescribed Drug Registry was initiated.) Matching was based on exact values of the cases’ covariates, except Drug Comorbidity Index, which was allowed to deviate 0.5 points. After matching, RS was estimated by dividing the ratio of overall survival of cases with overall survival of comparators, whereby the follow-up of comparators was censored according to the Ederer II method (i.e., at the time of death or censoring of their matched case). Furthermore, matching on age and year of diagnosis only was repeated using comparators 1 year younger than their matched cases, and then with comparators 2 years younger than their cases.

The analysis was performed using R, version 3.4.2 (Foundation for Statistical Computing, Vienna, Austria), using packages survival, relsurv, and Matching. The Research Ethics Board in Uppsala approved the study.

RESULTS

A total of 168,793 men diagnosed with PCa were registered in NPCR during the study period (Table 1). At date of PCa diagnosis, men older than 80 years, compared with men under 70, more often had advanced local tumor stage (T3–T4) (44% vs. 14%), higher PSA levels (median, 29 vs. 8 ng/mL), more often had Gleason score 8 or 9–10 (33% vs. 13%) and more often had distant metastases (14% vs. 6%). Furthermore, men over 80 almost never received primary radical treatment (1%), whereas 58% of men under 70 received primary radical treatment.

Relative versus cause-specific survival

The RS and CSS for the entire cohort at 5 years after diagnosis were 90% and 87%, respectively, and 84% and 77%, respectively, at 10 years. Men older than 80 with low-risk PCa at diagnosis had a particularly large difference between 5-year RS and CSS, 116% (95% confidence interval (CI): 112, 121) versus 96% (95% CI: 95, 97), and these differences were also seen in men with intermediate-risk PCa and to a lesser extent in men with high-risk PCa (Table 2, Figure 2).

In contrast, 5-year RS and CSS were similar for men under 70 with low-risk PCa, 103% (95% CI: 102, 103) versus 100% (95% CI: 100, 100), as well as for all men with regional or distant metastases, with a difference of 3% or less between RS and CSS estimates.

The difference between RS and CSS for men over 80 continued to increase at 10 years after diagnosis: 125% (95% CI: 113, 138) versus 85% (95% CI: 82, 88) for low-risk PCa and 109% (95% CI: 101, 117) versus 72% (95% CI: 69, 74) for intermediate-risk PCa. The difference in RS and CSS did not substantially increase at 10 years for men over 80 with high-risk disease or for regional or distant metastases (Table 2).

Ten-year RS in men under 70 with low-risk PCa was 105% (95% CI 105, 106) compared with a 10-year CSS of 99% (95% CI: 99, 99), whereas in men under 70 with regional or distant metastases RS and CSS were comparable, with a difference of 3% or less (Table 2).

Relative survival in men aged 80–89 years using matched comparators

After matching on comorbidity (based on Charlson Comorbidity Index and Drug Comorbidity Index), educational level, and marital/partnership status, the RS decreased from 116% to 106% at 5 years and from 120% to 104% at 10 years for men with low- or intermediate-risk PCa (Figure 3). The decline in RS was less pronounced in men with high-risk PCa and men with regional metastases. However, the RS of men with distant metastases remained essentially unchanged after additional matching.

The RS of men aged 80–89 years with low- or intermediate-risk PCa and those with high-risk PCa matched to comparators in Prostate Cancer data Base Sweden only by calendar year and age resulted in RS similar to that estimated by the life table method. Matching to comparators 1 year younger than their case resulted in RS similar to that from additionally matching by same age, comorbidity, educational level, and marital/partnership status (Figure 4). Matching to comparators 2 years younger led to further reduction in RS compared with the fully matched analysis, although still higher than CSS in men with low- or intermediate-risk PCa (Figure 5). Matching on comparators 1 or 2 years younger did not affect the RS of men with regional to distant metastasis at diagnosis.

DISCUSSION

In this population-based registry study, RS was substantially higher than CSS for men with low- and intermediate-risk PCa, in particular for men aged 80–89 years. For
Table 1. Baseline Characteristics for Men with Prostate Cancer in Prostate Cancer data Base Sweden, Version 4.1, According to Age at Diagnosis Between 1998–2016

| Characteristic                  | Age, years | <70 (n = 83,533) | 70–79 (n = 58,697) | ≥80 (n = 26,555) | Total (n = 168,793) |
|--------------------------------|------------|------------------|--------------------|------------------|--------------------|
|                                | No.        | %                | No.                | %                | No.                | %                |
| Age, years<sup>a</sup>         |            |                  |                    |                  |                    |                  |
| 64 (60, 67)                    | 47,491     | 57               | 22,384             | 38               | 6,000              | 23               | 75,875            | 45               |
| 74 (72, 77)                    | 23,018     | 28               | 19,578             | 33               | 8,660              | 33               | 51,257            | 30               |
| 83 (81, 85)                    | 9,944      | 12               | 12,927             | 22               | 9,069              | 34               | 31,943            | 19               |
| ≥80 (81, 85)                   | 1,548      | 2                | 2,204              | 4                | 1,943              | 7                | 5,697             | 3                |
| Missing                        | 1,532      | 2                | 1,604              | 3                | 883                | 3                | 4,021             | 2                |
| Clinical tumor stage           |            |                  |                    |                  |                    |                  |
| T1                             |            |                  |                    |                  |                    |                  |
| No.                            | 23,042     | 28               | 16,893             | 29               | 4,642              | 17               | 44,577            | 26               |
| T2                             |            |                  |                    |                  |                    |                  |
| No.                            | 4,681      | 6                | 5,805              | 10               | 3,739              | 14               | 14,227            | 8                |
| ≥T3                            |            |                  |                    |                  |                    |                  |
| No.                            | 55,810     | 67               | 35,999             | 61               | 18,174             | 68               | 109,989           | 65               |
| Node stage                     |            |                  |                    |                  |                    |                  |
| N0                             |            |                  |                    |                  |                    |                  |
| No.                            | 14,324     | 17               | 5,725              | 10               | 1,167              | 4                | 21,216            | 13               |
| N1                             |            |                  |                    |                  |                    |                  |
| No.                            | 1,866      | 2                | 1,026              | 2                | 322                | 1                | 3,215             | 2                |
| ≥Nx                            |            |                  |                    |                  |                    |                  |
| No.                            | 67,343     | 81               | 51,946             | 88               | 25,066             | 94               | 144,362           | 86               |
| Metastasis stage               |            |                  |                    |                  |                    |                  |
| M0<sup>b</sup>                |            |                  |                    |                  |                    |                  |
| No.                            | 23,042     | 28               | 16,893             | 29               | 4,642              | 17               | 44,577            | 26               |
| ≥M1                            |            |                  |                    |                  |                    |                  |
| No.                            | 4,681      | 6                | 5,805              | 10               | 3,739              | 14               | 14,227            | 8                |
| ≥Mx                            |            |                  |                    |                  |                    |                  |
| No.                            | 55,810     | 67               | 35,999             | 61               | 18,174             | 68               | 109,989           | 65               |
| Serum PSA ng/mL<sup>c</sup>   |            |                  |                    |                  |                    |                  |
| ≤10                            |            |                  |                    |                  |                    |                  |
| No.                            | 8 (5, 14)  |                  | 13 (7, 34)         |                  | 29 (13, 82)        |                  | 10 (6, 27)        |                  |
| 10–49.9                        |            |                  |                    |                  |                    |                  |
| No.                            | 52,326     | 63               | 22,199             | 38               | 4,366              | 16               | 78,891            | 47               |
| 50–99.9                        |            |                  |                    |                  |                    |                  |
| No.                            | 2,877      | 3                | 4,322              | 7                | 3,574              | 13               | 10,776            | 6                |
| ≥100                           |            |                  |                    |                  |                    |                  |
| No.                            | 4,479      | 5                | 6,584              | 11               | 5,498              | 21               | 16,566            | 10               |
| Missing                        | 1,228      | 1                | 1,739              | 3                | 1,084              | 4                | 4,051             | 2                |
| Gleason score                  |            |                  |                    |                  |                    |                  |
| ≤6                             |            |                  |                    |                  |                    |                  |
| No.                            | 42,909     | 51               | 19,723             | 34               | 5,153              | 19               | 67,785            | 40               |
| 7                              |            |                  |                    |                  |                    |                  |
| No.                            | 26,381     | 31               | 19,763             | 34               | 4,419              | 19               | 53,961            | 32               |
| 8                              |            |                  |                    |                  |                    |                  |
| No.                            | 5,700      | 7                | 6,489              | 11               | 4,424              | 16               | 16,313            | 10               |
| 9–10                           |            |                  |                    |                  |                    |                  |
| No.                            | 4,741      | 6                | 6,266              | 11               | 4,462              | 17               | 15,471            | 9                |
| WHO grade<sup>c</sup>         |            |                  |                    |                  |                    |                  |
| ≤3                             |            |                  |                    |                  |                    |                  |
| No.                            | 3,052      | 4                | 5,550              | 9                | 3,905              | 15               | 12,507            | 7                |
| ≥3                             |            |                  |                    |                  |                    |                  |
| No.                            | 750        | 1                | 906                | 2                | 1,095              | 4                | 2,756             | 2                |
| Primary treatment              |            |                  |                    |                  |                    |                  |
| Radiotherapy                   |            |                  |                    |                  |                    |                  |
| No.                            | 14,843     | 18               | 8,056              | 14               | 162                | 1                | 23,061            | 14               |
| ADT                            |            |                  |                    |                  |                    |                  |
| No.                            | 33,761     | 40               | 5,023              | 9                | 65                 | 0                | 38,849            | 23               |
| Radical prostatectomy          |            |                  |                    |                  |                    |                  |
| No.                            | 10,769     | 13               | 23,641             | 40               | 18,389             | 69               | 52,807            | 31               |
| AS or WW                       |            |                  |                    |                  |                    |                  |
| No.                            | 20,583     | 25               | 19,613             | 33               | 7,041              | 27               | 47,237            | 28               |
| Charlson Comorbidity Index     |            |                  |                    |                  |                    |                  |
| 0                               |            |                  |                    |                  |                    |                  |
| No.                            | 70,590     | 85               | 40,298             | 69               | 14,571             | 55               | 125,462           | 74               |
| 1                               |            |                  |                    |                  |                    |                  |
| No.                            | 7,756      | 9                | 9,655              | 16               | 5,770              | 22               | 23,184            | 14               |
| 2                               |            |                  |                    |                  |                    |                  |
| No.                            | 3,150      | 4                | 4,914              | 8                | 3,190              | 12               | 11,256            | 7                |
| ≥3                             |            |                  |                    |                  |                    |                  |
| No.                            | 2,037      | 2                | 3,830              | 7                | 3,024              | 11               | 8,891             | 5                |

Table continues
Net Survival for Men With Prostate Cancer

Table 1. Continued

| Characteristic                  | <70 (n = 83,533) | 70–79 (n = 58,697) | ≥80 (n = 26,555) | Total (n = 168,793) |
|---------------------------------|-----------------|--------------------|-----------------|--------------------|
|                                 | No.  | %    | No.  | %    | No.  | %    | No.  | %    |
| **Drug Comorbidity Index**      |      |      |      |      |      |      |      |      |
| (n = 83,533)                    | 0.6 (0, 1.5)    | 1.2 (0.4, 2.4)     | 2.0 (1.0, 3.4)  | 0.9 (0.3, 2.1)     |
| Educational level               |      |      |      |      |      |      |      |      |
| Low                             | 24,320| 29  | 26,559| 45  | 14,471| 54  | 65,353| 39  |
| Middle                          | 34,776| 42  | 20,535| 35  | 7,880 | 30  | 63,192| 37  |
| High                            | 24,007| 29  | 10,965| 19  | 3,524 | 13  | 38,497| 23  |
| Missing                         | 430  | 1   | 638  | 1   | 680  | 3   | 1,751 | 1   |
| Civil status                    |      |      |      |      |      |      |      |      |
| Married/partnership             | 56,437| 68  | 40,618| 69  | 16,065| 60  | 113,123| 67  |
| Unmarried                       | 27,050| 32  | 18,062| 31  | 10,488| 39  | 55,605| 33  |
| Missing                         | 46   | 0   | 17   | 0   | 2    | 0   | 65   | 0   |
| Risk category                   |      |      |      |      |      |      |      |      |
| Low risk                        | 32,010| 38  | 10,465| 18  | 1,613 | 6   | 44,088| 26  |
| Intermediate risk               | 25,926| 31  | 16,278| 28  | 4,140 | 16  | 46,344| 27  |
| High risk                       | 13,247| 16  | 16,391| 28  | 9,544 | 36  | 38,182| 23  |
| Regional metastases             | 3,835| 5   | 4,602 | 8   | 3,470 | 13  | 11,910| 7   |
| Distant metastases              | 6,714| 8   | 9,262 | 16  | 7,096 | 27  | 23,077| 14  |
| Missing                         | 1,801| 2   | 1,699 | 3   | 692  | 3   | 4,192 | 2   |

Abbreviations: ADT, androgen deprivation therapy; AS, active surveillance; PSA, prostate-specific antigen; WHO, World Health Organization; WW, watchful waiting.

a Values are expressed as median (interquartile range).
b M0: No signs of distant metastases on bone imaging.
c Only WHO grading available.
d Predicts individual’s overall mortality risk based on drug prescription history the previous year.
e Low: no more than 9 years (elementary school); intermediate: 9–12 years (secondary school); high: more than 12 years (college/university).
f Clinical stage (tumor, node, metastasis) T1–T2, Gleason score ≤6, and PSA <10 ng/mL.
g Clinical stage T1–T2 and Gleason score 7, or PSA 10–19.9 ng/mL.
h Clinical stage T3, Gleason score 9–10, or PSA 20–49.9 ng/mL.
i Clinical stage T4, N1, or PSA 50–99.9 ng/mL.
j M1 or PSA ≥100 ng/mL.

these men, RS was above 100%, suggesting that older men diagnosed with PCa are healthier than their age-matched comparators in the background population. The low CSS suggests misclassification bias resulting in an inflated proportion of very old men who were adjudicated PCa as cause of death. The “true” net survival lies between RS and CSS and is a useful metric of long-term outcome of cancer care. Combining results from these 2 frameworks of net survival is helpful to interpret changes in cancer mortality.

The NPCR of Sweden has a 98% capture rate compared with the Swedish Cancer Registry, to which reporting is mandated by law. Thus, our study included virtually all men diagnosed with prostate cancer in a well-defined population during a 19-year period with a recent end of follow-up. In addition, completeness and validity of data in NPCR have been assessed and found to be high, and we also had access to data of high quality from other national health-care registers and demographic databases (19–21). To our knowledge, this is the first study to compare 5- and 10-year RS and CSS in men with PCa according to age and risk categorization based on tumor stage, PSA levels, and Gleason score. Access to data on comorbidity and socioeconomic data in age-matched comparators allowed us to further investigate limitations in RS due to incomparability when using general population life tables.

Our study has some limitations. Despite the large study population, there were relatively few men aged 80–89 years who were alive 10 years after diagnosis. Matching analysis...
Table 2. Relative Survival and Cause-Specific Survival at 5 and 10 Years After Diagnosis of Prostate Cancer, According to Age Group and Risk Category, Among Men in the Prostate Cancer Data Base Sweden, Diagnosed Between 1998–2016

| Age Group and Risk Category | 5-Year Survival | 10-Year Survival |
|-----------------------------|----------------|------------------|
|                             | RS 95% CI      | CSS 95% CI       | RS 95% CI      | CSS 95% CI       |
| Low risk\(^a\)              |                |                  |                |                  |
| <70 years                   | 102.6 102.4, 102.8 99.9 99.7, 99.9 | 105.1 104.6, 105.6 98.9 98.8, 99.1 |
| 70–79 years                 | 108.1 107.3, 108.9 98.9 98.7, 99.1 | 114.5 112.5, 116.5 94.2 93.6, 94.9 |
| 80–89 years                 | 116.2 111.8, 120.8 95.8 94.6, 96.9 | 125.0 113.4, 137.7 85.0 82.1, 88.1 |
| Intermediate risk\(^b\)     |                |                  |                |                  |
| <70 years                   | 101.3 101.0, 101.6 99.1 99.0, 99.2 | 100.8 100.1, 101.5 96.1 95.8, 96.4 |
| 70–79 years                 | 104.4 103.7, 105.2 97.0 96.7, 97.3 | 100.8 99.0, 102.7 86.9 86.1, 87.7 |
| 80–89 years                 | 112.3 109.4, 115.3 92.0 91.0, 93.0 | 108.9 101.1, 117.2 71.5 69.0, 74.2 |
| High risk\(^c\)             |                |                  |                |                  |
| <70 years                   | 94.8 94.2, 95.4 94.2 93.8, 94.7 | 84.9 83.8, 86.1 84.0 83.2, 84.8 |
| 70–79 years                 | 91.7 90.7, 92.6 88.0 87.5, 88.6 | 75.0 73.3, 76.7 69.0 68.0, 70.0 |
| 80–89 years                 | 88.3 86.3, 90.4 76.4 75.3, 77.4 | 63.9 59.7, 68.5 50.1 48.2, 52.0 |
| Regional metastases\(^d\)   |                |                  |                |                  |
| <70 years                   | 79.6 78.0, 81.2 80.6 79.3, 82.0 | 57.9 55.7, 60.2 58.9 57.0, 60.9 |
| 70–79 years                 | 75.2 73.3, 77.1 75.3 73.9, 76.7 | 52.0 49.2, 55.0 51.0 49.0, 53.0 |
| 80–89 years                 | 68.0 64.8, 71.4 65.4 63.4, 67.4 | 44.2 38.4, 50.8 36.8 33.8, 40.1 |
| Distant metastases\(^e\)    |                |                  |                |                  |
| <70 years                   | 42.0 40.7, 43.4 44.7 43.4, 46.1 | 21.4 20.1, 22.8 24.1 22.8, 25.6 |
| 70–79 years                 | 40.8 39.5, 42.1 42.9 41.7, 44.1 | 20.8 19.4, 22.4 21.7 20.5, 23.0 |
| 80–89 years                 | 38.3 36.5, 40.3 35.1 33.7, 36.5 | 19.9 17.1, 23.2 15.4 13.9, 17.1 |

Abbreviation: CI, confidence interval, CSS, cause-specific survival; RS, relative survival.

\(^a\) Clinical (tumor, node, metastasis) stage T1–T2, Gleason score ≤6, and PSA <10 ng/mL.

\(^b\) Clinical stage T1–T2 and Gleason score 7, or PSA 10–19.9 ng/mL.

\(^c\) Clinical stage T3, Gleason score 9–10, or PSA 20–49.9 ng/mL.

\(^d\) Clinical stage T4, N1, or PSA 50–99.9 ng/mL.

\(^e\) M1 or PSA ≥100 ng/mL.

using a Drug Comorbidity Index could be performed only for men diagnosed during 2007–2016, because the Prescribed Drug Registry, on which this index is based, started in July 2005. Although this limits the number of cases in the study, we argue that the restriction in study period is an advantage because these results are more representative for men currently diagnosed with PCa than if we had used the entire NPCR with men diagnosed from 1998.

Our observations are in accordance with other studies on RS and CSS in men with PCa, which have all shown higher RS compared with CSS—and the difference has been higher in men with less-advanced cancer and in older men (6, 7, 9–11). In a recent study by Forjaz de Lacerda et al. (6), using data from the Surveillance, Epidemiology, and End Result (SEER) database, cancers commonly detected by screening had a slightly higher RS than CSS, whereas cancers with distinct risk factors (e.g., cervical cancer) had a higher CSS than RS. However, the SEER data only included men over age 65 years, and follow-up was only 5 years. In a population-based study from Norway, RS was markedly higher than CSS in men over age 85, and this difference increased with time from diagnosis (7).

The Ederer II method was used to estimate RS in our study. Newer methods are available, such as the Pohar-Perme estimator, which is considered the only truly unbiased estimator of net survival in that it adjusts for dependent censoring with inverse probability weighting (22). However, this method is susceptible to high variability in estimates of survival at long follow-up times, whereas the bias in the Ederer II method due to dependent censoring is negligible when the study population is stratified by age (23).

General population life tables include men with PCa when expected survival probabilities are estimated. For cancer at most sites other than the prostate this is not an important issue; however, PCa is a common disease among older men and accounts for 5%–7% of all deaths in Swedish men older than 80 years and will hence decrease survival in the general population (5, 24). Our analysis based on the comparison with PCa-free comparators was not affected by this bias.

In men with low- or intermediate-risk PCa, RS was substantially higher than CSS, in particular among men over
age 80. The reasons for this discrepancy are likely related to biases. In the relative survival framework, net survival is over estimated in older men with low-risk PCa due to a “healthy screening effect.” In our analysis, we were able to limit but not eliminate this bias by using comparators matched by age, comorbidity, educational level, and marital/partnership status. However, despite this matching, RS was still above 100% at 5 years after diagnosis for men with low- to intermediate-risk PCa. Unmeasured factors related to good health explain the higher survival rate of these men compared with the general population. Men diagnosed with PCa over age 80 are likely to be a selection of healthy men with a long life expectancy, because in order for a prostate biopsy to be considered for a man over 80, he must be fit. Furthermore, RS might be substantially affected by public health awareness and educational level, which could differ between populations.

The matching on age and calendar year was repeated using younger comparators to estimate the absolute difference in biological age of men with PCa compared with the general population of the same chronological age. Our results indicated that men aged 80–89 with low- or intermediate-risk PCa were biologically approximately 1 year younger than their chronological age. This difference might in fact be even larger; RS was still above 100% after this adjustment, which only accounted for differences in comorbidity, educational level, and marital/partnership status.

Cause-specific survival relies on correct assessment of the cause of death, and this is likely increasingly difficult with age because very old men often have high comorbidity. According to a study by Fall et al. (25), the validity of the Cause of Death Registry in Sweden was high for PCa death. Nevertheless, in that study, men over age 75 had a 5% higher risk of PCa death in the Cause of Death Registry compared with adjudication of PCa death after review of medical records, and this is possibly even higher in very old men with low-risk PCa and multiple comorbidities, who

Figure 2. Relative and cause-specific survival according to age and risk category, among Swedish men after diagnosis of prostate cancer in 1998–2016. A) Low and intermediate risk; B) high risk; C) regional metastases; D) distant metastases.
are more likely to die from competing causes than of their PCa.

In men with regional or distant metastatic PCa at diagnosis, RS and CSS resulted in very similar estimates in all age groups. The risk of misclassifying cause of death in men with advanced disease at diagnosis is small because most of these men die from PCa. Furthermore, men with metastatic PCa are likely more similar to the background population in terms of general health than men with low-risk PCa, because a symptomatic man is likely to undergo prostate biopsy even if he is frail.

RS is considered the preferred framework for estimating net survival in population-based cancer studies because there is a risk of misclassifying cause of death, which is the basis for CSS (8). However, in our study both RS and CSS provided biased estimates of net survival in men with low- or intermediate-risk PCa, in particular among very old men. RS provided unrealistically high survival estimates, above 100%, whereas CSS provided unrealistically low survival estimates. Thus, the true net survival will be between the estimates of RS and CCS.

The interpretation of data on mortality in men with PCa is difficult due to old age at diagnosis, long disease trajectory, and high competing risk for death. For example, in Sweden there has been a recent increase in life expectancy, with a >40% decrease in death from myocardial infarction, leaving more older men at risk of a PCa diagnosis and PCa death (5). Hence, progress in PCa treatment might not be fully mirrored by the number of men who die of PCa. Furthermore, screening will lead to diagnoses of men with low- and intermediate-risk PCa, and despite the low biological risk of progression these men have a substantial
risk of having their death incorrectly assessed as caused by PCa.

Both RS and CSS are affected by biases that drive the estimates in opposite directions. RS overestimates net survival whereas CSS underestimates it. The preferred method of net survival analysis depends on the underlying assumptions that therefore need to be evaluated considering the disease under study, characteristics of the population, and reliability of the adjudication of cause of death. The “true” net survival aims to measure the disease course in the absence of competing risk and lies somewhere between the estimates obtained by RS and CSS. Therefore, RS and CSS can be used to interpret changes in mortality rates, especially in men with PCa, of whom most die of other causes. We argue that our findings are generalizable to other populations with a similar age distribution, PCa incidence, and health-care system.

With an aging population and more widespread screening in the near future in many countries, the number of older men diagnosed with low-risk PCa will increase. The importance of correctly assessing net survival in these men will therefore be essential to evaluate cancer care. For this group of men, our access to PCa-free comparators allowed us to overcome a significant amount of bias due to incomparability in relative survival. In future studies, access to a comparative cancer-free cohort can be useful to complement analysis of net survival, and further matching on characteristics might be warranted to effectively overcome residual incomparability bias.

In conclusion, net survival is an important metric for assessing cancer care and is measured by relative survival or cause-specific survival. For men with low- and intermediate-risk PCa, both relative survival and cause-specific survival
provide biased estimates of net survival. Relative survival overestimates survival and cause-specific survival underestimates survival, and the difference is particularly strong among very old men. The “true” estimate of net survival for these men will be between the estimates of relative survival and cause-specific survival. For young men and in particular in men with advanced PCa, relative survival and cause-specific survival yield very similar estimates.

ACKNOWLEDGMENTS

Author affiliations: Department of Surgical Sciences, Uppsala University Hospital, Uppsala, Sweden (Andri Wilberg Orrason, Hans Garmo, Pär Stattin); Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden (Johan Styrke); and Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden (Paul W. Dickman).

This project was made possible by the continuous work of the National Prostate Cancer Register of Sweden (NPCR) steering group: Dr. Pär Stattin (chairman), Dr. Ingela Franck Lissbrant (co-chair), Dr. Camilla Thellenberg, Dr. Eva Johansson, Dr. Lennart Åström, Dr. Magnus Törnblom, Dr. Stefan Carlsson, Marie Hjälm Eriksson, Dr. David Robinson, Mats Andén, Dr. Ola Bratt, Dr. Jonas Hugosson, Maria Nyberg, Dr. Per Fransson, Fredrik Sandin, and Karin Hellström.
This study was supported by the Swedish Research Council (2017 00847), the Swedish Cancer Society (2016 0700), and Uppsala County Council.

Data availability statement: The data underlying this article were accessed from Prostate Cancer data Base Sweden. The derived data generated in this research will be shared on reasonable request to the corresponding author, on remote server access.

The supporting grants were unconditional, and the funding organizations had no influence on the work performed.

Conflict of interest: none declared.

REFERENCES

1. Taitt HE. Global trends and prostate cancer: a review of incidence, detection, and mortality as influenced by race, ethnicity, and geographic location. *Am J Mens Health*. 2018;12(6):1807–1823.

2. World Health Organization. Global Health Observatory. Geneva, Switzerland: World Health Organization. https://www.who.int/data/gho/. Accessed January 10, 2020.

3. Teo MY, Rathkopf DE, Kantoff P. Treatment of advanced prostate cancer. *Annu Rev Med*. 2019;70:479–499.

4. National Prostate Cancer Registry Sweden. Yearly report on prostate cancer [in Swedish]. 2018; http://npcr.se/wp-content/uploads/2019/09/20190905_npcr_nationell_rapport_2018.pdf. Accessed January 10, 2020.

5. Swedish National Board of Health and Welfare. Cause of Death Statistics. https://sdh.socialstyrelsen.se/sfd_dor/val.aspx. Accessed January 10, 2020.

6. Forjaz de Lacerda G, Howlader N, Mariotto AB. Differences in cancer survival with relative versus cause-specific approaches: an update using more accurate life tables. *Cancer Epidemiol Biomarkers Prev*. 2019;28(9):1544–1551.

7. Skyrud KD, Bray F, Møller B. A comparison of relative and cause-specific survival by cancer site, age and time since diagnosis. *Int J Cancer*. 2014;135(1):196–203.

8. Dickman PW, Adami HO. Interpreting trends in cancer patient survival. *J Intern Med*. 2006;260(2):103–117.

9. Makkar N, Ostrem QT, Kruchko C, et al. A comparison of relative survival and cause-specific survival methods to measure net survival in cancer populations. *Cancer Med*. 2018;7(9):4773–4780.

10. Withrow DR, Pole JD, Nishri ED, et al. Choice of relative or cause-specific approach to cancer survival analysis impacts estimates differentially by cancer type, population, and application: evidence from a Canadian population-based cohort study. *Popul Health Metr*. 2017;15(1):24.

11. Howlader N, Ries L, Mariotto A, et al. Improved estimates of cancer-specific survival rates from population-based data. *J Natl Cancer Inst*. 2010;102(20):1584–1598.

12. Van Hemelrijck M, Garmo H, Wigertz A, et al. Cohort profile update: the National Prostate Cancer Register of Sweden and prostate cancer data base—a refined prostate cancer trajectory. *Int J Epidemiol*. 2016;45(1):73–82.

13. Ederer FHH. Instructions to IBM 650 Programmers in Processing Survival Computations. Methodological Note No. 10. End Results Evaluation Section. Bethesda, MD: National Cancer Institute 1959.

14. The Human Mortality Database. https://www.mortality.org/. Accessed January 8, 2019.

15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. *J Am Stat Assoc*. 1958;53(282):457–481.

16. Brenner H, Rachet B. Hybrid analysis for up-to-date long-term survival rates in cancer registries with delayed recording of incident cases. *Eur J Cancer*. 2004;40(16):2494–2501.

17. Sundararajan V, Henderson T, Perry C, et al. New ICD-10 version of the Charlson Comorbidity Index predicted in-hospital mortality. *J Clin Epidemiol*. 2004;57(12):1288–1294.

18. Gedeborg R, Garmo H, Robinson D, et al. Prescription-based prediction of baseline mortality risk among older men. *PLoS One*. 2020;15(10):e0241439.

19. Tomic K, Berglund A, Robinson D, et al. Capture rate and representativity of the National Prostate Cancer Register of Sweden. *Acta Oncol*. 2015;54(2):158–163.

20. Tomic K, Sandin F, Wigertz A, et al. Evaluation of data quality in the National Prostate Cancer Register of Sweden. *Eur J Cancer*. 2015;51(1):101–111.

21. Tomic K, Westerberg M, Robinson D, et al. Proportion and characteristics of men with unknown risk category in the National Prostate Cancer Register of Sweden. *Acta Oncol*. 2016;55(12):1461–1466.

22. Perme MP, Stare J, Estève J. On estimation in relative survival. *Biometrics*. 2012;68(1):113–120.

23. Lambert PC, Dickman PW, Rutherford MJ. Comparison of different approaches to estimating age standardized net survival. *BMC Med Res Methodol*. 2015;15(1):64.

24. Talbäck M, Dickman PW. Estimating expected survival probabilities for relative survival analysis—exploring the impact of including cancer patient mortality in the calculations. *Eur J Cancer*. 2011;47(17):2626–2632.

25. Fall K, Strömberg F, Rosell J, et al. Reliability of death certificates in prostate cancer patients. *Scand J Urol Nephrol*. 2008;42(4):352–357.